Amentum Holdings, Inc. (AMTM)
시가총액: 5.31B
국가: United States
산업: None
섹터: None
홈페이지: https://www.amentum.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 3.49B / -- / -- / -- / 2.0%
2412: 3.42B / -- / -- / -- / -4.2%
2409: 3.57B / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.53 / 0.26 / 103.8% / -- / 3.9%
2412: 0.51 / -- / -- / -- / 8.5%
2409: 0.47 / -- / -- / -- / --

- 연간 매출(YoY%), EPS(YoY%)

#AMTM

- 사업요약: Amentum Holdings, Inc. provides engineering and technology solutions to the U.S. and allied government agencies. It offers supporting programs of critical national importance across energy and environmental, intelligence, space, defense, civilian, and commercial end-markets. It offers a range of capabilities, including environment and climate sustainability, intelligence and counter threat solutions, data fusion and analytics, engineering and integration, advanced test, training and readiness, and citizen solutions. The company was incorporated in 2023 and is headquartered in Chantilly, Vir...

Commercial Vehicle Group, Inc. (CVGI)
시가총액: 28.83M
국가: United States
산업: #Auto_Parts_OEM
섹터: #Consumer_Discretionary
홈페이지: https://cvgrp.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 169.8M / 169.44M / 0.2% / -26.8% / 4.0%
2412: 163.3M / 220.49M / -25.9% / -26.8% / -4.9%
2409: 171.8M / 222.06M / -22.6% / -30.4% / -25.3%
2406: 229.9M / 237.73M / -3.3% / -12.3% / -0.9%
2403: 232.07M / -- / -- / -11.7% / 4.0%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.08 / -0.01 / -700.0% / -188.9% / 46.7%
2412: -0.15 / -0.03 / -400.0% / -- / -1400.0%
2409: -0.01 / 0.04 / -125.0% / -104.5% / -116.7%
2406: 0.06 / 0.17 / -64.7% / -80.0% / -33.3%
2403: 0.09 / -- / -- / -65.4% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 994.68M(1.3%) / --(--)
2212: 981.55M(1.0%) / -0.68(-194.4%)
2112: 971.58M(35.4%) / 0.72(160.0%)
2012: 717.7M(--) / -1.2(-335.3%)

#CVGI

- 사업요약: Commercial Vehicle Group, Inc., together with its subsidiaries, designs, manufactures, assembles, and sells systems, assemblies, and components to commercial and electri...

Eupraxia Pharmaceuticals Inc. (EPRX)
시가총액: 143.43M
국가: Canada
산업: #Pharmaceuticals_and_Biotechnology
섹터: #Health_Care
홈페이지: https://www.eupraxiapharma.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 0.00 / -- / -- / --
2412: 0.00 / 0.00 / -- / -- / --
2403: 0.0 / -- / -- / -- / --
2312: 0.0 / -- / -- / -- / --
2309: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.1897 / -0.1729 / -9.7% / 9.7% / 9.8%
2412: -0.2104 / -0.1247 / -68.7% / -- / --
2403: -0.21 / -- / -- / -16.7% / --
2312: -- / -- / -- / -- / --
2309: -0.26 / -- / -- / -- / 27.8%

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(--) / -1.17(-21.9%)
2212: 0.0(--) / -0.96(48.9%)
2112: 0.0(--) / -1.88(-505.1%)
2012: 0.0(--) / -0.310697(--)

#EPRX

- 사업요약: Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of...

PhenixFIN Corporation (PFX)
시가총액: 99.47M
국가: United States
산업: #Finance_Consumer_Services
섹터: #Finance
홈페이지: https://www.phenixfc.com/

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 6.02M / 5.78M / 4.2% / -23.7% / -3.2%
2412: 6.22M / 6.79M / -8.4% / -11.2% / 11.7%
2409: 5.57M / 6.98M / -20.2% / -42.3% / -10.6%
2406: 6.23M / 5.17M / 20.5% / -44.0% / -21.1%
2403: 7.89M / -- / -- / -6.8% / 12.7%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.4819 / 0.64 / -24.7% / -81.6% / -70.6%
2412: 1.64 / 0.94 / 74.5% / -25.1% / 613.0%
2409: 0.23 / 1.15 / -80.0% / -- / -82.2%
2406: 1.29 / 0.65 / 98.5% / -69.7% / -50.8%
2403: 2.62 / -- / -- / -18.1% / 19.6%

- 연간 매출(YoY%), EPS(YoY%)
2309: 35.01M(2844.9%) / 12.87(589.4%)
2209: 1.19M(-85.6%) / -2.63(-647.9%)
2109: 8.24M(113.6%) / 0.48(102.0%)
2009: -60383425.0(--) / -24.16(--)

#PFX

- 사업요약: PhenixFIN Corporation is a business development company. The firm seeks to invest in privately negotiated debt and equity securities of small and middle market companies. It primarily inve...

Genelux Corporation (GNLX)
시가총액: 93.61M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.genelux.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -100.0% / --
2409: 0.00 / -- / -- / -- / --
2406: 0.00 / -- / -- / -- / -100.0%
2403: 8.0K / -- / -- / -95.3% / --
2312: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.21 / -0.22 / 4.5% / 27.6% / --
2409: -0.19 / -0.25 / 24.0% / 5.0% / 13.6%
2406: -0.22 / -0.24 / 8.3% / 4.3% / 24.1%
2403: -0.29 / -- / -- / 45.3% / --
2312: -- / -- / -- / -- / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 170000.0(-98.5%) / --(--)
2212: 11.07M(--) / -0.220918(68.1%)
2112: 0.0(--) / -0.692591(-20.0%)
2012: 0.0(--) / -0.576933(--)

#GNLX

- 사업요약: Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a...

WideOpenWest, Inc. (WOW)
시가총액: 367.09M
국가: United States
산업: #Cable_and_Other_Pay_Television_Services
섹터: #Telecommunications
홈페이지: https://www.wowway.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 150M / 148.27M / 1.2% / -7.1% / -1.7%
2412: 152.6M / 154.42M / -1.2% / -9.6% / -3.4%
2409: 158M / 157.46M / 0.3% / -8.7% / -0.5%
2406: 158.8M / 159.14M / -0.2% / -8.0% / -1.7%
2403: 161.5M / -- / -- / -6.2% / -4.3%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.17 / -0.2067 / 17.8% / 5.6% / -30.8%
2412: -0.13 / -0.13 / 0.0% / -- / 51.9%
2409: -0.27 / -0.1 / -170.0% / 79.1% / -107.7%
2406: -0.13 / -0.14 / 7.1% / 89.6% / 27.8%
2403: -0.18 / -- / -- / 60.9% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 686.7M(-2.6%) / -3.53(-11666.7%)
2212: 704.9M(-2.9%) / -0.03(-100.3%)
2112: 725.7M(-0.6%) / 9.31(5072.2%)
2012: 730.2M(--) / 0.18(--)

#WOW

- 사업요약: WideOpenWest, Inc. provides high speed data, cable television, and digital telephony services to residential and business services customers in the United States. The company'...

Denali Therapeutics Inc. (DNLI)
시가총액: 2.03B
국가: United States
산업: #Biotechnology_Biological_Products_No_Diagnostic_Substances
섹터: #Health_Care
홈페이지: https://www.denalitherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / 1.7M / -100.0% / -- / --
2412: 0.00 / 12.75M / -100.0% / -- / --
2409: 0.00 / 6.3M / -100.0% / -100.0% / -100.0%
2406: 1.5M / 10M / -85.0% / -99.5% / --
2403: 0.0 / -- / -- / -100.0% / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.78 / -0.7 / -11.4% / -14.7% / -16.4%
2412: -0.67 / -0.84 / 20.2% / 22.1% / -6.3%
2409: -0.63 / -0.6041 / -4.3% / 12.5% / -6.8%
2406: -0.59 / -0.67 / 11.9% / -145.4% / 13.2%
2403: -0.68 / -- / -- / 15.0% / 20.9%

- 연간 매출(YoY%), EPS(YoY%)
2312: 330.53M(204.7%) / --(--)
2212: 108.46M(122.9%) / -2.6(-8.8%)
2112: 48.66M(-85.5%) / -2.39(-479.4%)
2012: 335.66M(--) / 0.63(130.4%)

#DNLI

- 사업요약: Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegener...

Adicet Bio, Inc. (ACET)
시가총액: 50.27M
국가: United States
산업: #Biotechnology_Pharmaceutical_Preparations
섹터: #Health_Care
홈페이지: https://www.adicetbio.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 0.00 / -- / -- / -- / --
2412: 0.00 / -- / -- / -- / --
2409: 0.00 / -- / -- / -- / --
2406: 0.00 / -- / -- / -- / --
2403: 0.0 / -- / -- / -- / --

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.31 / -0.33 / 6.1% / 11.4% / 3.1%
2412: -0.32 / -0.35 / 8.6% / -- / 5.9%
2409: -0.34 / -0.34 / 0.0% / 70.7% / -3.0%
2406: -0.33 / -0.36 / 8.3% / 56.0% / 5.7%
2403: -0.35 / -- / -- / 51.4% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 0.0(-100.0%) / -3.31(-94.7%)
2212: 24.99M(156.8%) / -1.7(15.0%)
2112: 9.73M(-45.7%) / -2.0(60.1%)
2012: 17.9M(--) / -5.01(--)

#ACET

- 사업요약: Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate dur...

Lyra Therapeutics, Inc. (LYRA)
시가총액: 6.72M
국가: United States
산업: #Medical_Dental_Instruments
섹터: #Health_Care
홈페이지: https://lyratherapeutics.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 183K / 102.35K / 78.8% / -65.6% / -12.4%
2412: 209K / 324.4K / -35.6% / 43.2% / 7.2%
2409: 195K / 315.6K / -38.2% / -64.2% / -67.4%
2406: 598K / 342.4K / 74.6% / 30.6% / 12.4%
2403: 532.0K / -- / -- / 29.8% / 264.4%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: -0.13 / -0.12 / -8.3% / 62.9% / 18.8%
2412: -0.16 / -0.1925 / 16.9% / -- / 11.1%
2409: -0.18 / -0.22 / 18.2% / 33.3% / 75.7%
2406: -0.74 / -0.3289 / -125.0% / -105.6% / -111.4%
2403: -0.35 / -- / -- / 20.5% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 1.56M(14.3%) / -1.26(31.1%)
2212: 1.36M(378.2%) / -1.83(45.4%)
2112: 285000.0(--) / -3.35(-29.3%)
2012: 0.0(--) / -2.59(--)

#LYRA

- 사업요약: Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatm...

ProAssurance Corporation (PRA)
시가총액: 1.17B
국가: United States
산업: #Property_Casualty_Insurers
섹터: #Finance
홈페이지: https://www.proassurance.com

- 분기 매출(공시, 예측, 서프, YoY, QoQ)
2503: 236.28M / 228.66M / 3.3% / -16.1% / -18.6%
2412: 290.1M / 228.42M / 27.0% / -1.9% / 1.7%
2409: 285.25M / 231.13M / 23.4% / 3.4% / -1.8%
2406: 290.35M / 235.61M / 23.2% / 1.8% / 3.1%
2403: 281.73M / -- / -- / 2.9% / -4.7%

- 분기 EPS(공시, 예측, 서프, YoY, QoQ)
2503: 0.13 / 0.1917 / -32.2% / 44.4% / -63.9%
2412: 0.36 / 0.18 / 100.0% / -- / 5.9%
2409: 0.34 / 0.14 / 142.9% / 135.8% / 47.8%
2406: 0.23 / 0.11 / 109.1% / 15.0% / 155.6%
2403: 0.09 / -- / -- / 181.8% / --

- 연간 매출(YoY%), EPS(YoY%)
2312: 1.13B(2.6%) / -0.73(-7200.0%)
2212: 1.1B(2.5%) / -0.01(-100.4%)
2112: 1.08B(21.3%) / 2.67(181.8%)
2012: 886.86M(--) / -3.262481(--)

#PRA

- 사업요약: ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property...